SAVANNAH, GA--(Marketwired - March 27, 2014) -
MIT Holding, Inc. (OTCQB: MITD
) announces that it was awarded a contract to coordinate, conduct and administer FDA clinical trials for SERRG Savannah Inc.
a Multi-Specialty Research Organization. The contract engages MITD
immediately and is an open and ongoing agreement for additional trails.
Walter Drakeford, President MIT Holding, stated, "Our facility, staff and their attention to detail, patient care and comfort exceeded SERRG investigators expectations during the per-contract awarding process. We have trained every employee to put the patients' care and comfort first. Our facility and staff was a logical choice for SERRG given the patients concern in a blind clinical trial."
For further information and news about the Company click the following:
Click here for recent news on MITD.
Click here for current SEC filings for MITD.
About MIT Holding, Inc.:
Through its wholly owned subsidiaries, MIT distributes wholesale pharmaceuticals in the United States, administers intravenous infusions and, in Georgia, operates ambulatory centers where therapies are administered and sells and rents home medical equipment. MIT has initiated government contacts to obtain the necessary approvals to import pharmaceutical products into the Americas. MIT's domestic wholesale pharmaceutical distribution is conducted through Medical Infusion Technologies, Inc., which sells pharmaceuticals to end-users and other wholesalers in the U.S.
About SERRG, Inc.:
SERRG, Inc. is a clinical research organization that is distinctly different from any research organization you've ever worked with. SERRG, Inc. is a true Multi-Specialty Research Organization, with a "hands-on" approach from contract to close-out. Every aspect of the research process is managed by our highly specialized and dedicated teams.
For more information, contact Mr. William Nalley, Orsay Groupe, email@example.com, phone 305-515-8077 and/or visit http://www.mitholdingsinc.com/home-2.
This news release contains "forward-looking statements" as that term is defined in Section 27A of the United States Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements regarding beliefs, plans, expectations or intentions contain reasonable expectations, but there can be no assurance that such beliefs, plans, expectations or intentions will prove to be accurate.